表紙
市場調查報告書

關注市場分析:神經膠質母細胞瘤

Market Spotlight: Glioblastoma

出版商 Datamonitor Healthcare 商品編碼 914879
出版日期 內容資訊 英文 65 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:神經膠質母細胞瘤 Market Spotlight: Glioblastoma
出版日期: 2020年07月31日內容資訊: 英文 65 Pages
簡介

Datamonitor Healthcare ,估計2017年的全球神經膠質母細胞瘤的發病案例約有70,000萬案例,至2026年其數量增加到87,100案例。

本報告提供全球神經膠質母細胞瘤市場調查,疾病的背景、概要,患病人數的10年預測,開發平台藥物及已上市藥物概要,臨床試驗狀況,授權、資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等資料彙整。

概要

要點

疾病的背景

  • 疾病定義
  • 患者區分
  • 症狀
  • 風險因素
  • 診斷

治療

  • 外科手術
  • 放射線治療
  • 化療
  • 腫瘤治療電場 (TTF)
  • 標靶治療

流行病學

已上市藥物

開發平台藥物

近幾年的活動、分析師的見解

主要的活動

成功的可能性

授權、資產收購等的交易

本源專利

商機

臨床試驗環境

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0204048

This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 77,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 91,800 incident cases by 2028.

It is estimated that the majority of diagnosed cases were in males in 2019. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intratumoral, and oral routes for glioblastoma.

The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with three drugs in the NDA/BLA phase.

Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I/II trial results for Calquence and NOX-A12, topline Phase II trial results for ABI-009, topline Phase II/III trial results for omburtamab, Phase III updated trial results for DCVax-Brain and Trans Sodium Crocetinate (TSC), and expected PDUFA dates for biosimilar bevacizumab (Mylan/Biocon) and Danyelza.

The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 43.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.

The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 79 trials.

Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, followed by Roche

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Tumor-treating fields (TTFs)
  • Targeted therapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • AG-881 for Glioblastoma (May 29, 2020)
  • FT-2102 for Glioblastoma (May 28, 2020)
  • Toca 511 for Glioblastoma (September 12, 2019)
  • Opdivo for Glioblastoma (September 5, 2019)
  • Mvasi for Glioblastoma (June 25, 2019)
  • GammaTile for Glioblastoma (June 17, 2019)
  • Qinlock for Glioblastoma (June 11, 2019)
  • AG-881 for Glioblastoma (June 3, 2019)
  • Multiple Drugs for Glioblastoma (June 3, 2019)
  • Opdivo for Glioblastoma (May 9, 2019)
  • Optune for Glioblastoma (April 23, 2019)
  • Optune for Glioblastoma (February 28, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • New Approvals In Spotlight As China Gears For National Congress
  • Mylan Reveals FDA Goal Date For Bevacizumab
  • Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • HLB Takes First Expansion Step Via Immunomic Acquisition
  • Fosun Gains Chinese Rights To MimiVax's SurVaxM
  • Deals Shaping The Medical Industry, October 2019

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of glioblastoma, 2019-28
  • Figure 2: Overview of pipeline drugs for glioblastoma in the US
  • Figure 3: Pipeline drugs for glioblastoma, by company
  • Figure 4: Pipeline drugs for glioblastoma, by drug type
  • Figure 5: Pipeline drugs for glioblastoma, by classification
  • Figure 6: FT-2102 for Glioblastoma (May 28, 2020): Phase I/II - 2101-ONC-102
  • Figure 7: Toca 511 for Glioblastoma (September 12, 2019): Phase III - Toca 5 (w/Lomustine)
  • Figure 8: Opdivo for Glioblastoma (September 5, 2019): Phase III - CheckMate-548
  • Figure 9: Opdivo for Glioblastoma (May 9, 2019): Phase III - CheckMate 498 (vs. Temozolomide)
  • Figure 10: Key upcoming events in glioblastoma
  • Figure 11: Probability of success in the glioblastoma pipeline
  • Figure 12: Clinical trials in glioblastoma
  • Figure 13: Top 10 drugs for clinical trials in glioblastoma
  • Figure 14: Top 10 companies for clinical trials in glioblastoma
  • Figure 15: Trial locations in glioblastoma
  • Figure 16: Glioblastoma trials status
  • Figure 17: Glioblastoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Global incident cases of glioblastoma, 2019-28
  • Table 2: Incident cases of glioblastoma, by gender, 2019
  • Table 3: Marketed drugs for glioblastoma
  • Table 4: Pipeline drugs for glioblastoma in the US
  • Table 5: AG-881 for Glioblastoma (May 29, 2020)
  • Table 6: FT-2102 for Glioblastoma (May 28, 2020)
  • Table 7: Toca 511 for Glioblastoma (September 12, 2019)
  • Table 8: Opdivo for Glioblastoma (September 5, 2019)
  • Table 9: Mvasi for Glioblastoma (June 25, 2019)
  • Table 10: GammaTile for Glioblastoma (June 17, 2019)
  • Table 11: Ripretinib for Glioblastoma (June 11, 2019)
  • Table 12: AG-881 for Glioblastoma (June 3, 2019)
  • Table 13: Multiple Drugs for Glioblastoma (June 3, 2019)
  • Table 14: Opdivo for Glioblastoma (May 9, 2019)
  • Table 15: Optune for Glioblastoma (April 23, 2019)
  • Table 16: Optune for Glioblastoma (February 28, 2019)
  • Table 17: Historical global sales, by drug ($m), 2015-19
  • Table 18: Forecasted global sales, by drug ($m), 2020-24